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One hundred and one pre-treatment primary central primitive neuroectodermal tumours were analysed for the expression of
p53 protein by immunohistochemistry using the monoclonal antibody DO-7. The staining intensity was classiﬁed into four
groups: strong, medium, weak and negative and strong staining intensity was associated with the poorest survival. DNA
sequencing of the p53 gene was performed in 28 cases representing all four staining groups. Mutations were found in only
three of the strong staining tumours suggesting that DNA mutations were not common events and that in the majority of the
tumours with over-expressed p53, the protein was likely to be wild-type. Results of immunohistochemistry showed a
signiﬁcantly positive relationship between the expression of p53 and Bax and Bcl-2 proteins, but not Waf-1. Multivariate
analyses supported the prognostic value of p53 immunostaining in central primitive neuroectodermal tumours and also of age
and gender of patients.
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Primitive neuroectodermal tumours of the central nervous system
(cPNETs) account for 6–8% of all brain tumours and for 12–
25% of paediatric brain tumours (Roberts et al, 1991). These
malignant tumours frequently occur between the ages of 3 and
12 and between 50–70 (de Vita et al, 1982) and are sensitive to
radiotherapy (Chang et al, 1969). With advances in radiotherapy,
neurosurgery and better supportive care, overall survival rates have
been greatly improved in the last two decades from 24 to 82%.
Speciﬁcally, 70% of patients survive for up to 5 years (Cervoni
and Cantore, 1995). However, cranio-spinal radiotherapy causes
undesirable long-term sequelae in the young age group, including
stunted growth and loss of intellectual function. The use of adju-
vant chemotherapy in permitting the reduction of radiotherapy
dose is currently being investigated.
Awiderangeof clinicalandbiologicalfactors havebeen studiedfor
theireffectsonpatientsurvivalinthehopeofidentifyinghighriskand
low risk groups in order to tailor aggressive treatment regimens
according to patient prognosis. Among clinical factors studied are
patients’ age and gender extent of tumour resection and presence of
metastasis at diagnosis (Tomita and McLone, 1986; Cervoni and
Cantore,1995;Sureetal,1995;Weiletal,1998).Thebiologicaldisease
features studied include expression of p53, loss of heterozygosity
(LOH) of chromosome 17, differentiation markers and DNA ploidy
(Yasue et al, 1989; Saylors et al, 1991; Badiali et al, 1993; Wang et al,
1998). Thus far, a reliable marker of disease outcome remains to be
identiﬁed,althoughithasbeennotedthatthemostfrequentlyreported
featureincPNETsisLOHofchromosome17p,inparticulartheregion
containingthep53genelocusandfurthertelomerictoit(Thomasand
Raffel, 1991; Albrecht, 1994). The p53 gene has been reported to be
mutated in most cancers (Levine, 1997), and mutant p53 proteins
often accumulate in the nucleus because their altered conformation
endows them with a property to escape normal degradation.
Our group has previously reported the prognostic value of the
immunohistochemical staining intensity of p53 protein in a series
of 88 cPNETs (Jaros et al, 1993). In the previous study, immuno-
histochemistry for p53 was performed without any form of antigen
retrieval and high intensity of immunohistochemical staining was
signiﬁcantly associated with poor patient survival. In the current
study, immunohistochemistry was performed with microwaving
for 85 cases of the original series of cPNETs and 16 new cases.
The relationship between the intensity of p53 staining and patient
survival was also investigated. As the accumulation of p53 protein
in cells could be the result of normal reaction to genotoxic stress
by wild-type p53 or of mutations in the p53 gene (Hainaut,
1995) not distinguishable by DO-7 immuno-staining, the coding
regions of the p53 gene were sequenced in selective samples to
establish the p53 gene status. The expression of other proteins
involved in the p53 pathway as downstream mediators of p53 func-
tion, i.e. Waf-1, Bax and Bcl-2 (El-Deiry et al, 1993; Miyashita et
al, 1994a,b; Miyashita and Reed, 1995), was also studied by immu-
nohistochemistry, and their prognostic value was investigated by
survival analyses. Finally, the expression of the above proteins,
patients’ age, sex and year of diagnosis were entered into a multi-
variate analysis.
MATERIALS AND METHODS
Patient samples
One hundred and one patients presenting with cPNETs (including
80 medulloblastomas) in the Northern region between 1963 and
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Table 1 Primer pairs used in PCR and DNA sequencing for exons 2, 3, 4, 10 and 11 of the p53
gene; four primers were used for exon 4, to generate products corresponding to two fragments
from each half of the exon
Exon Orientation Location Position* Sequence
2 SN Int1 11677-90 5'-TGGATCCTCTTGCAGCAG-3'
ASN Ex2/Int2 11778-805 5'-CAATGGATCCACTCACAG-3'
3 SN Ex2/Int2 11778-805 5'-CTGTGAGTGGATCCATTG-3'
ASN Ex3/Int3 11922-42 5'-AACCCTTGTCCTTACCAGAA-3'
4 SN (A) Ex3/Int3 11921-40 5'-GTTCTGGTAAGGACAAGGGT-3'
ASN (B) Int4 12331-50 5'-ATACGGCCAGGCATTGAAGT-3'
SN (C) Ex4 12105-24 5'-ATGAAGCTCCCAGAATGCCA-3'
ASN (D) Ex4 12199-218 5'-AAGGGACAGAAGATGACAGG-3'
10 SN Int9/Ex10 17557-74 5'-CTCTGTTGCTGCAGATCC-3'
ASN Ex10/Int10 17673-92 5'-GCTGAGGTCACTCACCTGGA-'3
11 SN Int10/Ex11 18581-98 5'GCTTCTGTCTCCTACAGC-3'
ASN Int11 18773-88 5'-TGACGCACACCTATTGC-3'
Position*: nucleotide positions based on GENBANK DNA library; Bold bases: exonic sequences. Int: intron;
Ex: exon; SN: sense; ASN: anti-sense.
Figure 1 (A) Negative p53 staining in a Purkinje cell (P), and in the synaptic areas (S) in the space surrounding the granule cells. (B) Positive p53 staining in
glioblastoma multiforme used as positive control. (C) Positive p53 immunostaining in cPNET. (D) Negative staining for p53 in cPNET. (E) Weak Waf-1
staining was observed in Purkinje cell (P) while adjacent granule cells were negative. (F) Strong nuclear staining of Waf-1 in breast carcinoma cells used
as positive control. (G) Strong nuclear staining of Waf-1 in cPNET. (H) cPNET negative for Waf-1. (I) Moderate staining of Bax in the cytoplasm and den-
drites of Purkinje cell. (J) Strong cytoplasmic staining of Bax in tonsil tissue (positive control). (K) Positive cytoplasmic staining of Bax by 13666E in cPNETs.
(L) Negative staining of Bax in cPNET. (M) Postive Bcl-2 staining in the molecular layer of normal cerebellum. (N) Positive cytoplasmic staining of Bcl-2 in
tonsil (control tissue). (O) High LI of Bcl-2 staining in cPNET. (P) Bcl-2 staining mainly outside pale islands in desmoplastic medulloblastoma.
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mentioned above (Jaros et al, 1993) and 16 new cases. Patient
samples were obtained from surgery, formalin-ﬁxed and embedded
in parafﬁn blocks. All were pre-treatment tissues, i.e. none of the
patients had pre-operative radiotherapy or chemotherapy. All
patients had attempted surgical removal of the primary tumour
which resulted in either partial or total resection. The majority
had craniospinal radiotherapy with a boost to the centre of the
primary tumour, and some of those treated in the 1990s also
received chemotherapy. Diagnosis of the tumours was made by
the consultant neuropathologists in post, and the majority reviewed
by two neuropathologists. For the purpose of the study, all pathol-
ogy was reviewed by Professor Perry. Patient information was
extracted from a combination of sources: patients’ clinical notes
obtained from the Medical Records, Newcastle General Hospital,
and Middlesbrough General Hospital, and the ‘Children and Young
Persons’ Malignant Disease Registry’ at the Sir James Spence Insti-
tute of Child Health, Royal Victoria Inﬁrmary (RVI), Newcastle
Upon Tyne.
Immunohistochemistry: antibodies and controls
A standard immunohistochemical staining method, described
previously (Jaros et al, 1993), was performed in conjunction with
an antigen retrieval technique. Prior to incubation with the primary
antibody, sections were placed in citrate buffer and microwaved at
high power for 10 min. Positive and negative controls were set up
with every experiment. The same procedures were used for samples
and the positive and negative controls, except that the primary anti-
body was omitted from the negative control. The antibodies used for
p53, Waf-1, Bax and Bcl-2 were DO-7 (Novocastra) AB-1 (Onco-
gene), 13666E (Pharmingen) and 124 (Dako) and diluted at 1:50,
1:20, 1:1200 and 1:100, respectively. The control tissue used for
p53 was obtained from a glioblastoma multiforme (GBM) parafﬁn-
embedded tumour block. Sections from this block had previously
been found to stain positive for DO-7 (Jaros et al, 1993). The control
tissue used for Waf-1 staining was breast tumour tissue, and that for
both Bax and Bcl-2 was tonsil tissue. The labelling index (LI) for each
antibody was deﬁned as the percentage of the number of positive
nuclei (p53 and Waf-1), cytoplasm (Bcl-2) or both (Bax) in 1000
tumour cells. The staining intensity (SI) was deﬁned with reference
to the positive control (strong) and could be categorised into four
groups: strong (A), medium (B), weak (C) and negative (D). Both
LI and SI were assessed by two observers using a light microscope,
with 95% consensus.
DNA extraction from parafﬁn-embedded samples,
PCR ampliﬁcation and direct sequencing of exons 2–11
of the p53 gene
Genomic DNA was extracted from eight cases from p53 group A,
11 from groups B and C, and nine from group D for DNA sequen-
cing. The procedures for extracting DNA from parafﬁn-embedded
tissues, PCR ampliﬁcation and direct sequencing of exons 4–9 of
the p53 gene from genomic DNA, using the biotin method for
puriﬁcation of a single-stranded template, and the sequences of
the primer pairs, have previously been described in detail (Challen
et al, 1992). The sequences for primers corresponding to exons 2,
3, 10 and 11, and a new pair for exon 4, are described in Table 1.
Labelling of PCR product for exon 5 of the p53 gene
This method was applied to all samples to detect the presence of an
18 bp deletion in exon 5 which was identiﬁed in one sample
during sequencing. A radiolabelled nucleotide a-
32P-dATP was
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Figure 2 Distribution for LI for p53 (A), Waf-1 (B), Bax (C) and Bcl-2 (D) proteins in cPNETs.
Table 2 The numbers of cPNETs in each SI and LI category for p53,
Waf-1, Bax and Bcl-2
SI
Proteins A B C D LI Total
p53 12 26 31 32 520%=17 101
520%=84
Waf-1 15 26 29 22 40%=70 92
0%=22
Bax 27 21 23 17 580%=48 88
580%=40
Bcl-2 ––––40%=39 101
0%=62
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lamide gel electrophoresis and subsequent phosphorimaging or
autoradiography. Slight adjustment was made to the dNTP (deox-
ynucleotide triphosphate) contents in the PCR mixture, to
maintain the dATP concentration within adequate limits for reac-
tion efﬁciency and ﬁdelity during PCR.
Survival analyses
The Kaplan–Meier method (Graphpad Prism) was used to esti-
mate survival probability as a function of time, and the log-rank
test to examine differences in survival between subgroups. Multi-
variate analysis for p53 SI and LI, age, sex and year of diagnosis
(YOD), was performed by Cox’s regression using the forward step-
wise selection method (SPSS statistical software package).
RESULTS
Immunohistochemical analysis
Detection of p53, Waf-1, Bax and Bcl-2 proteins in normal
cerebellar tissue p53 and Waf-1 were not detectable in normal
cerebellar tissues present in 10 tumour sections (Figure 1A, E).
Bax was detected in normal cerebellar tissues, mostly in the cyto-
plasm (Figure 1I). Normal astrocytes were negative whereas
reactive astrocytes were moderately stained. The staining of Bcl-
2 in normal cerebellar tissue was generally weak, with Purkinje
cells and other neurons being weakly or not stained at all (Figure
1M).
Detection of p53, Waf-1, Bax and Bcl-2 proteins in control
tissue Detection of p53, Waf-1, Bax and Bcl-2 in the corresponding
control tissue waspositive andstrong, asexpected (Figure1B,F,J,N).
Detection of p53, Waf-1, Bax and Bcl-2 proteins in
cPNETs In cPNETs both positive and negative staining were
observed for all four proteins (Figure 1C, G, K, O). A range of
SI and LI was observed, but the majority of tumours showed weak
to moderate staining. Both p53 and Waf-1 staining was localised to
the nucleus, while Bax staining was observed in nucleus and cyto-
plasm. The staining of Bcl-2 was localised to the cytoplasm.
Examples of negative staining for p53, Waf-1, Bax and Bcl-2 are
shown in Figures 1(D, H, L, P) respectively. The distribution of
the number of cPNETs in each LI and SI category for each protein
is shown in Table 2 and Figure 2 (A–D).
DNA sequencing of the p53 gene and PCR/direct labelling
DNA sequencing identiﬁed alterations in exon 5 of the p53 gene in
three samples from immunostaining group A, including missense
mutations in exon 5 of the p53 gene in two samples (Figure 3A,
B), and an in-frame deletion of 18 base pairs, corresponding to
codons 275–280, in a third sample. This deletion was conﬁrmed
by PCR-direct size analysis (Figure 4A, B) but no evidence of this
deletion was found in the other 27 cases analysed by this method.
A single base alteration in the DNA sequence of p53 was also
detected in intron 6 in a sample which was negative for p53.
Prognostic factors in cPNETs
The prognostic value of the accumulation of p53, Waf-1, Bax and
Bcl-2 proteins was assessed by both univariate and multivariate
analyses, using the Kaplan–Meier method and Cox’s regression,
respectively. The overall survival of the patients studied (n=101)
was 35% at 5 years. The accumulation of p53 protein, which in
the majority of cases was wild-type, has signiﬁcant prognostic value
(Figure 5) in this series of cPNETs, with high SI (group A) relating
to poor survival (P50.0001, Log rank test). No signiﬁcant differ-
ence in survival was observed between groups categorised for
Waf-1, Bax and Bcl-2 staining. The categories and corresponding
P-values for the survival analysis for each protein are shown in
Table 3. Other factors, gender, age, and year of diagnosis, were also
subjected to both univariate and multivariate analyses, and were
found to be independently prognostic in the multivariate analyses
(Table 4). However, of all the factors studied in the multivariate
analyses, immunohistochemical staining of p53 had the strongest
independent prognostic value.
DISCUSSION
p53 protein expression was detected in the majority of the 101
cPNETs in this study, but only 12 of these (11.9%) had high stain-
ing intensity. The level of staining of p53 in the present study,
which employed microwaving for antigen retrieval in the immuno-
histochemistry was consistent with that of a previous study (Jaros
et al, 1993), in which no antigen retrieval was employed. DNA
sequencing results indicated that p53 gene mutations in this series
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T      C      G      A T      C      G      A
Normal Mutated
Normal Deleted
13201
13218
Codon 277 Ex 8
Cys Tyr
TGT TAT
A
B
Figure 3 Mutations found in the p53 gene in two cPNETs by DNA
sequencing. (A) Missense mutation at codon 277 in exon 8 in one cPNET.
The panel on the left shows a normal sequence, and the one on the right
depicts the sequence harbouring the point mutation at codon 277. (B)A n
18-bp region in exon 5 was deleted in one cPNET. The sequence in the
panel on the left depicts a normal sequence with nucleotides 13201–
13218 highlighted, which are missing in the sample on the right.
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from other studies (Saylors et al, 1991; Adesina, 1994) and could
explain the high sensitivity of medulloblastoma cells to radio-
therapy (Chang et al, 1969).
The low incidence of p53 gene mutations in these cPNETs
suggested that the p53 protein in these tumours was likely to be
wild-type and functional. This was consistent with the signiﬁcantly
positive relationship between the expression of p53 and Bax (Table
5) which is a known target of p53 transcriptional activity (Miya-
shita and Reed, 1995). The expression of wild-type p53 in cPNETs
may reﬂect a normal cellular response to the stressful microenvir-
onment in the tumours, including nutrient deprivation, hypoxia
and redox imbalance which would induce and stabilise WTp53
up-regulation (Graeber et al, 1994; An et al, 1998). Normal cells
in such conditions would have undergone apoptosis, but it is likely
that in some of these tumours, apoptosis was inhibited by the
presence of Bcl-2. On the other hand, the expression of Waf-1
did not relate to that of p53 in these tumours (Table 5) which
might not be unexpected, as Waf-1 expression is not exclusively
controlled by p53 (Halevy et al, 1995; Russo et al, 1995; Liu et
al, 1996). However, disturbance in the expression of Waf-1 protein
in cells which over-express non-functional wild-type p53 has been
reported in gliomas and glioma cell lines (Pykett et al, 1998) and
the lack of relationship between the expression of these two
proteins has also been reported in colorectal carcinoma (Slebos
et al, 1996) and breast carcinoma (Barbareschi et al, 1996).
Contrary to p53 and Bax, the positive relationship between the
expression of p53 and Bcl-2 proteins in the cPNETs (Table 5)
was unexpected, as an inverse correlation between the expression
of the two proteins would have been predicted, based on the
current understanding of the suppressive function of p53 on Bcl-
2 transcription (Seto et al, 1992; Miyashita et al, 1994a,b). This
observation could be the result of induction of p53 in response
to the elevated levels of Bcl-2, which could in turn be the result
of a factor or mechanism that has given rise to the tumours. A
likely candidate for this factor or mechanism was growth factor/
receptor or oncogene de-regulation, as some of the tumours in this
study have been found to over-express erbB2, a member of the
epidermal growth factor receptor or EGFR family (Gilbertson et
al, 1997, 1998).
In conclusion, the present study has shown that a high level of
p53 protein in cPNETs measured by immunostaining intensity was
associated with poor patient survival, supporting the ﬁndings of a
previous study, and appeared to reﬂect the aggressiveness of the
tumours. Sequencing results and the overall positive relationship
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Figure 5 (A) Kaplan–Meier survival analysis found that expression of
p53 had signiﬁcant prognostic value in cPNETs, with a high intensity of
DO-7 staining associated signiﬁcantly with poorest survival (P50.0001,
log rank tested). When samples diagnosed before and after 1979 were
analysed separately ((B) and (C) respectively), high intensity of DO-7 stain-
ing retained its prognostic signiﬁcance (P=0.0074 and P50.0001, respec-
tively). n=number of samples; P=P-value; w
2=chi square value of the test.
Other cPNETs
cPNET N
A
B
No 65
Figure 4 The autoradiographs of two acrylamide gels illustrate examples of the bands representing a
32P-dATP-labelled PCR products generated from
PCR of p53 exon 5. In (A), the band representing the truncated product from the cPNET (sample number 65) harbouring the deletion was viewed against
that of another cPNET with a normal sized product and a sequencing ladder of a plasmid. In (B), the products from another cPNETs with a normal exon 5
were run alongside those from sample 65. A normal tissue control (N) was included in the reaction to generate a PCR product of the expected size for
comparison.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1117–1123between the expression of p53 and Bax pointed to the possibility
that the p53 protein in the current series of cPNETs was wild-type
and functional, except in the subset of tumours which expressed
high levels of Bcl-2. In addition, maleness, young age at diagnosis
and diagnosis before 1979 were all independent indicators of poor
prognosis. Further research work, including functional assays invol-
ving reporter systems in cell lines and studies investigating the
mechanisms underlying the expression of Bcl-2 in cPNETs, will
clarify the functional status of p53 in central primitive neuroecto-
dermal tumours.
ACKNOWLEDGEMENTS
This study was sponsored by the North of England Children’s
Cancer Research Campaign. Patient survival data was retrieved
from the Children and Young Person’s Malignant Disease Registry
with the help of Lorna More. Many thanks to the staff at the
Neuropathology Department of the Newcastle General Hospital.
REFERENCES
Adesina A (1994) p53 gene mutation and Mdm2 gene ampliﬁcation are
uncommon in medulloblastoma. Cancer Res 54: 5649–5651
Albrecht S (1994) Microsatellite analysis of loss of heterozygosity on chromo-
somes 9q 11p and 17p in medulloblastomas. Neuropathol Applied
Neurobiol 20: 74–81
An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM
(1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha.
Nature 392: 405–408
Badiali M, Iolascon A, Loda M, Scheithauer BW, Basso G, Trentini GP,
Giangaspero F (1993) p53 gene mutations in medulloblastoma. Immuno-
histochemistry gel shift analysis and sequencing. Diagn Mol Pathol 2: 23–
28
Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R,
Morelli L, Leonardi E, Bevilacqua G, Dalla Palma P, Harris AL (1996)
p21WAF1 immunohistochemical expressin in breast carcinoma: correla-
tions with clinicopathological data oestrogen receptor status MIB1
expression p53 gene and protein alterations and relapse-free survival. Br
J Cancer 74: 208–215
Cervoni L, Cantore G (1995) Medulloblastoma in pediatric age: a single insti-
tuiton review of prognostic factors. Child’s Nerv Syst 11: 80–85
Challen C, Lunec J, Warren W, Collier J, Bassendine MF (1992) Analysis of
TP53 tumour suppressor gene in hepatocellular carcinomas from Britain.
Hepatology 16: 1362–1366
Chang CH, Housepian EM, Herbert C (1969) An operative staging system
and a megavoltage radiotherapeutic technic for cerebellar medulloblasto-
mas. Radiology 93: 1351–1359
de Vita VT, Hellman S, Rosenberg SA (1982) Cancer: Principles and Practice of
Oncology Philadelphia: J.B. Lippincott Co.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D,
Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1 a potential mediator
of p53 tumor suppression. Cell 75: 817–825
Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH,
Kelly P, Pearson AD, Lunce J (1998) Expression of the ErbB-neuregulin
signaling network during human cerebellar development: implication for
the biology for the biology of medulloblastoma. Cancer Res 58: 3932–3941
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 3 Summary of results of univariate analyses for the expression of
p53, Waf-1, Bcl-2, Bax, age, gender and year of diagnosis in cPNETs
Univariate model
Factor Hazard 95% CI
No. (sample size) P-value ratio of ratio
1 p53420% (17) 0.067 1.78 0.95–4.5
p53520% (84) 1
2 p53 A (12) 50.001
p53 B (26)
p53 C (31)
p53 D (32)
3 Waf-1 40% (23) 0.540 0.83 0.44–1.55
Waf-1 50% (69) 1
4 Waf-1 A (15) 0.900
Waf-1 B (26)
Waf-1 C (29)
Waf-1 D (22)
5 Bax 480% (48) 0.826 1.06 0.6–1.87
Bax 580% (40) 1
6 Bax A (28) 0.167
Bax B (20)
Bax C (23)
Bax D (17)
7 Bcl-2 40% (38) 0.220 1.36 0.81–2.38
Bcl-2=0% (63) 1
8 Age 57 (51) 0.099 1.51 0.92–2.57
Age 47 (50) 1
9 Female (36) 0.038 0.57 0.35–0.97
Male (65) 1
10 YOD 51979 (53) 0.005 2.08 1.27–3.60
YOD 41979 (48) 1
Table 4 Multivariate analysis results for the SI of p53, age, gender and
year of diagnosis in cPNETs. p53 SI has the strongest prognostic value
Multivariate model
95% CI
No. Factor P-value HR of ratio
1 p53 A (12) 50.001 9.14 3.548–23.563
p53 B (26) 1.00 0.451–2.213
p53 C (31) 0.82 0.358–1.859
p53 D (32) 1 –
2 Age 57 (51) 0.026 1.53 0.924–2.591
Age 47 (50) 1
3 Female (36) 0.005 0.56 0.343–0.973
Male (65) 1
4 YOD 41979 (53) 0.05 0.54 0.3–1.0
YOD 51979 (48) 1
Table 5 The relationship between the expression of p53, Waf-1, Bax
and Bcl-2 in cPNETs
P53 SI Waf-1 SI Bax SI Bcl-2 SLI
P53 SI – P=0.56 P=0.0011 P=0.016
w
2=7.75 w
2=22.31 w
2=10.36
Waf-1 SI – – P=0.079 P=0.147
w
2=11.3 w
2=5.4
Bax SI – – – P=0.046
w
2=8.0
Bcl-2 LI – – – –
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